OR Royalties (NYSE:OR) Lowered to "Buy" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded OR Royalties from "strong-buy" to "buy", but the consensus remains a Moderate Buy with an average analyst price target of $46.50 (1 Strong Buy, 5 Buy, 4 Hold).
• Shares trade around $39.42 (50‑day $40.80, 200‑day $38.11) with a $7.4B market cap and PE of 36.17; the latest quarter delivered $0.32 EPS (beat by $0.01) and $90.47M revenue (slightly below estimates).
• Institutional ownership is high at about 68.5%, and Goldman Sachs materially increased its stake—raising holdings by 152% (adding ~758,815 shares) in the latest reported period.

OR Royalties (NYSE:OR - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research note issued to investors on Saturday.

Other equities analysts also recently issued reports about the company. Royal Bank Of Canada reiterated an "outperform" rating and set a $56.00 target price on shares of OR Royalties in a research report on Friday. Scotiabank increased their target price on OR Royalties from $41.00 to $51.00 and gave the stock a "sector perform" rating in a research report on Monday, January 26th. Canadian Imperial Bank of Commerce reiterated an "outperform" rating on shares of OR Royalties in a research report on Wednesday, February 4th. Weiss Ratings reiterated a "buy (b)" rating on shares of OR Royalties in a research report on Monday, December 29th. Finally, TD Securities restated a "hold" rating on shares of OR Royalties in a report on Monday, February 23rd. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $46.50.

OR Royalties Trading Down 0.6%

NYSE OR opened at $39.42 on Friday. The business's 50-day moving average price is $40.80 and its 200 day moving average price is $38.11. OR Royalties has a twelve month low of $21.93 and a twelve month high of $48.06. The company has a market capitalization of $7.40 billion, a PE ratio of 36.17 and a beta of 0.83.

OR Royalties (NYSE:OR - Get Free Report) last released its earnings results on Wednesday, February 18th. The basic materials company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.01. OR Royalties had a return on equity of 12.41% and a net margin of 74.30%.The firm had revenue of $90.47 million for the quarter, compared to the consensus estimate of $90.80 million. Equities analysts predict that OR Royalties will post 0.62 EPS for the current year.

Institutional Investors Weigh In On OR Royalties

Several hedge funds have recently modified their holdings of OR. Goldman Sachs Group Inc. raised its holdings in shares of OR Royalties by 152.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,256,583 shares of the basic materials company's stock valued at $26,539,000 after buying an additional 758,815 shares during the period. Geode Capital Management LLC grew its stake in OR Royalties by 2.7% during the 2nd quarter. Geode Capital Management LLC now owns 92,267 shares of the basic materials company's stock valued at $2,384,000 after purchasing an additional 2,459 shares in the last quarter. Cetera Investment Advisers grew its stake in OR Royalties by 3.5% during the 2nd quarter. Cetera Investment Advisers now owns 13,147 shares of the basic materials company's stock valued at $337,000 after purchasing an additional 440 shares in the last quarter. JPMorgan Chase & Co. grew its stake in OR Royalties by 58.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 205,176 shares of the basic materials company's stock valued at $5,275,000 after purchasing an additional 75,596 shares in the last quarter. Finally, Gamco Investors INC. ET AL purchased a new position in shares of OR Royalties during the 2nd quarter valued at approximately $1,051,000. 68.52% of the stock is currently owned by hedge funds and other institutional investors.

OR Royalties Company Profile

OR Royalties PLC NYSE: OR is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company's core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.